Rheum Round-up: FDA Warns About Tofacitinib, Pandemic Effect on Osteoporosis, and more
Tofacitinib May Increase Risk of Heart-related Problems, Cancer: FDA Alert
The FDA recently issued an alert pertaining to tofacitinib, used in the treatment of arthritis...
COVID-19 Pandemic Led To Medication Interruptions, Delayed DXA Scans in Osteoporosis Patients
Patients with osteoporosis experienced medication interruptions and delayed Dual-energy X-ray Absorptiometry (DXA) scans, according to a global survey.
"The survey indicates that the identification and...
Is Hysterectomy Associated with Increased Risk of Osteoporosis?
A study published in PLOS One found that women who have undergone a hysterectomy may be at an increased risk of developing osteoporosis or...
Denosumab Versus Alendronate for Osteoporosis in Patients Receiving Long-Term Glucocorticoids
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate for patients with osteoporosis receiving long-term glucocorticoids...
Physicians Are Not Widely Screening for Osteoporosis in Men
An article published in Endocrine Practice observed heterogeneity in osteoporosis screening patterns in male patients among surveyed primary care physicians, endocrinologists, and geriatricians.
Researchers surveyed...
Should Osteoporosis Medication Be Discontinued During the COVID-19 Pandemic?
A study published in Aging supports the continued use of antiosteoporosis medications during the COVID-19 pandemic, speculating that some of these agents may even...
Rheum Round-up: Blood Test to Guide RA Treatment, COVID’s Osteoporosis Impact, and more
A Blood Test May Help Determine Which Patients with RA Will Respond to Treatment
A new study found that blood biomarkers may be useful in...
